JP5317270B2 - 医用画像のための短いアミノアルコール鎖および金属錯体を含む化合物 - Google Patents

医用画像のための短いアミノアルコール鎖および金属錯体を含む化合物 Download PDF

Info

Publication number
JP5317270B2
JP5317270B2 JP2008534029A JP2008534029A JP5317270B2 JP 5317270 B2 JP5317270 B2 JP 5317270B2 JP 2008534029 A JP2008534029 A JP 2008534029A JP 2008534029 A JP2008534029 A JP 2008534029A JP 5317270 B2 JP5317270 B2 JP 5317270B2
Authority
JP
Japan
Prior art keywords
compound
formula
complex
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008534029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009513574A (ja
Inventor
マール ポール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guerbet SA
Original Assignee
Guerbet SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guerbet SA filed Critical Guerbet SA
Publication of JP2009513574A publication Critical patent/JP2009513574A/ja
Application granted granted Critical
Publication of JP5317270B2 publication Critical patent/JP5317270B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C07C211/05—Mono-, di- or tri-ethylamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2008534029A 2005-10-07 2006-10-09 医用画像のための短いアミノアルコール鎖および金属錯体を含む化合物 Active JP5317270B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0510289A FR2891830B1 (fr) 2005-10-07 2005-10-07 Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
FR0510289 2005-10-07
US73475605P 2005-11-09 2005-11-09
US60/734,756 2005-11-09
PCT/EP2006/067214 WO2007042506A1 (en) 2005-10-07 2006-10-09 Compounds comprising short aminoalcohol chains and metal complexes for medical imaging

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013105720A Division JP5731572B2 (ja) 2005-10-07 2013-05-20 医用画像のための短いアミノアルコール鎖および金属錯体を含む化合物

Publications (2)

Publication Number Publication Date
JP2009513574A JP2009513574A (ja) 2009-04-02
JP5317270B2 true JP5317270B2 (ja) 2013-10-16

Family

ID=36636179

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008534029A Active JP5317270B2 (ja) 2005-10-07 2006-10-09 医用画像のための短いアミノアルコール鎖および金属錯体を含む化合物
JP2013105720A Active JP5731572B2 (ja) 2005-10-07 2013-05-20 医用画像のための短いアミノアルコール鎖および金属錯体を含む化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013105720A Active JP5731572B2 (ja) 2005-10-07 2013-05-20 医用画像のための短いアミノアルコール鎖および金属錯体を含む化合物

Country Status (16)

Country Link
US (1) US8114863B2 (enExample)
EP (2) EP2457914B1 (enExample)
JP (2) JP5317270B2 (enExample)
KR (2) KR20080080495A (enExample)
CN (2) CN101305006B (enExample)
BE (1) BE2024C510I2 (enExample)
BR (1) BRPI0617151B8 (enExample)
CA (1) CA2625207C (enExample)
DK (1) DK1931673T3 (enExample)
ES (2) ES2519369T3 (enExample)
FI (1) FIC20240003I1 (enExample)
FR (2) FR2891830B1 (enExample)
NL (1) NL301259I2 (enExample)
PL (1) PL1931673T3 (enExample)
PT (1) PT1931673E (enExample)
WO (1) WO2007042506A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013209400A (ja) * 2005-10-07 2013-10-10 Guerbet 医用画像のための短いアミノアルコール鎖および金属錯体を含む化合物

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2914303A1 (fr) * 2007-03-28 2008-10-03 Guerbet Sa Composes pour le diagnostic de l'apoptose.
US8378134B2 (en) 2009-09-30 2013-02-19 General Electric Company Hydroxylated contrast enhancement agents
US20110077396A1 (en) * 2009-09-30 2011-03-31 General Electric Company Intermediates for hydroxylated contrast enhancement agents
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
DK2766364T3 (da) * 2011-08-17 2024-09-30 Merck & Cie Folatkonjugater af albumin-bindende enheder
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
CA2909919C (fr) * 2013-04-26 2022-07-12 Guerbet Formulation de produit de contraste et son procede de preparation associe
CN103467504B (zh) * 2013-09-23 2015-06-24 武汉工程大学 18f-氟标记卟啉-异氮杂茚自由基配合物及合成方法
CN104485193B (zh) * 2014-12-29 2016-11-02 广西师范大学 一种以酰腙类希夫碱为配体构筑的磁性材料及其制备方法
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
FR3039767B1 (fr) 2015-08-04 2017-09-08 Guerbet Sa Composition destinee a vectoriser un agent anticancereux
HUE060536T2 (hu) * 2015-12-10 2023-03-28 Bracco Imaging Spa Dimer kontrasztanyagok
EP3223181B1 (en) 2016-03-24 2019-12-18 Sofradim Production System and method of generating a model and simulating an effect on a surgical repair site
WO2017178301A1 (en) * 2016-04-13 2017-10-19 Bracco Imaging Spa Contrast agents
GB201610738D0 (en) * 2016-06-20 2016-08-03 Ge Healthcare As Chelate compounds
EP3544964B1 (en) 2016-11-28 2020-06-17 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
CN110290815A (zh) 2016-12-21 2019-09-27 通用电气医疗集团股份有限公司 适合作为mri显像剂的基于四氮杂双环-大环的锰螯合化合物
FR3069245B1 (fr) * 2017-07-21 2019-07-26 Guerbet Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales
US11110186B2 (en) 2017-12-20 2021-09-07 General Electric Company Anionic chelate compounds
US10973934B2 (en) * 2018-08-06 2021-04-13 Bracco Imaging S.P.A. Gadolinium bearing PCTA-based contrast agents
DE102018126558A1 (de) * 2018-10-24 2020-04-30 Helmholtz-Zentrum Dresden - Rossendorf E.V. Markierungsvorläufer mit Quadratsäure-Kopplung
IL321215B2 (en) 2018-11-23 2026-05-01 Bayer Ag Contrast media formulation and process for its preparation
FR3091873B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification
US11370804B2 (en) 2019-01-17 2022-06-28 Guerbet Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process
FR3091872B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de synthese
US11426470B2 (en) 2019-01-17 2022-08-30 Guerbet Complex of gadolinium and a chelating ligand derived of a diastereoisomerically enriched PCTA and synthesis method
KR102588221B1 (ko) * 2020-07-16 2023-10-13 게르브 2-브로모글루타르산 디에스테르를 합성하는 방법
CN111875667B (zh) * 2020-07-16 2021-12-21 南方科技大学 有机金属螯合物及其制备方法与应用、探针
US20230339945A1 (en) 2020-07-17 2023-10-26 Guerbet Method for preparing a chelating ligand derived from pcta
CN114105983B (zh) * 2021-11-09 2023-08-11 国科温州研究院(温州生物材料与工程研究所) 手性1,4,7,10-四氮杂-2,6-吡啶环蕃衍生物及其金属螯合物的制备和应用
KR102845061B1 (ko) * 2022-09-01 2025-08-13 주식회사 테라노큐어 신규한 화합물 및 이를 포함하는 mri 조영제
CN119698423A (zh) * 2022-09-01 2025-03-25 泰瑞诺科有限公司 新型化合物以及包含其的mri造影剂
WO2024215535A2 (en) * 2023-04-03 2024-10-17 Molecular Theranostics, Llc Extradomain b fibronectin targeting peptides and derivatives for cancer imaging and therapy
EP4464708A1 (en) 2023-05-17 2024-11-20 Bayer Aktiengesellschaft New contrast agents for use in diagnostic imaging
WO2025045168A1 (zh) 2023-09-01 2025-03-06 江苏恒瑞医药股份有限公司 一种大环化合物及其用途
CN118834263B (zh) * 2024-09-14 2024-12-03 成都施贝康生物医药科技有限公司 含短氨基醇链的化合物及其金属络合物和应用
CN118791488B (zh) * 2024-09-14 2024-11-15 成都施贝康生物医药科技有限公司 化合物、螯合物及其在磁共振成像中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135748A (en) 1960-05-27 1964-06-02 Little Inc A Heterocyclic substituted carbodhmides and method of preparation
DE4001655A1 (de) * 1990-01-18 1991-07-25 Schering Ag 6-ring enthaltende makrocyclische tetraaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5334371A (en) 1988-07-20 1994-08-02 Schering Aktiengesellschaft Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI
DE3825040A1 (de) * 1988-07-20 1990-01-25 Schering Ag, 13353 Berlin 5- oder 6-ring- enthaltende makrocyclische polyaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5554748A (en) 1989-04-07 1996-09-10 Nycomed Salutar, Inc. Adducts of macrocyclic chelants
DE69230970T2 (de) 1991-12-10 2001-01-04 The Dow Chemical Co., Midland Bicylclische, polyazamakrocyclocarbonsäure-komplexe, konjugate, herstellung und verwendung als kontraststoffe
DE69426811T2 (de) * 1993-12-30 2001-09-13 Guerbet, Villepinte Polyaminierte Liganden, Metallkomplexe, Verfahren zur Herstellung und diagnostische und therapeutische Verwendungen
EP0971747B1 (en) 1996-10-28 2005-12-28 Amersham Health AS Contrast agents
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6071490A (en) 1998-05-07 2000-06-06 Immunomedics, Inc. Position emission tomography using gallium-68 chelates
FR2793795B1 (fr) 1999-05-21 2001-08-03 Guerbet Sa Isomeres de tetramides du complexe de gadolinium de l'acide (1,4,7,10-tetrazacyclododecane)1,4,7,10-tetra(2-glutarique) leur procede de preparation et leur application en imagerie medicale
FR2794744B1 (fr) * 1999-06-09 2001-09-21 Guerbet Sa Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
CA2376245A1 (en) 1999-07-29 2001-02-08 Dyax Corp. Binding moieties for fibrin
WO2001052900A2 (en) * 2000-01-21 2001-07-26 Mallinckrodt Inc. Novel orthogonally protected amino acid chelators for biomedical applications
US6450956B1 (en) 2000-11-06 2002-09-17 Siemens Corporate Research, Inc. System and method for treatment and outcome measurement analysis
ITMI20011518A1 (it) * 2001-07-17 2003-01-17 Bracco Imaging Spa Leganti azotati multidentati capaci di complessare ioni metallici e loro uso in diagnostica e in terapia
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
FR2836916B1 (fr) * 2002-03-05 2004-06-11 Guerbet Sa Oligomeres de chelates de gadolinium, leur application comme produits de contraste en imagerie par resonance magnetique et leurs intermediaires de synthese
WO2005001415A2 (en) 2003-05-23 2005-01-06 Epix Pharmaceuticals, Inc. Optically pure and enriched isomers of chelating ligands and contrast agents
FR2856689A1 (fr) 2003-06-25 2004-12-31 Guerbet Sa Composes specifiques a forte relaxivite
SG177216A1 (en) 2003-07-24 2012-01-30 Bracco Imaging Spa Stable radiopharmaceutical compositions and methods for their preparation
US20050136003A1 (en) 2003-10-31 2005-06-23 Casebier David S. Novel chemical agents comprising a cardiotonic moiety and an imaging moiety and methods of their use
GB0326546D0 (en) 2003-11-14 2003-12-17 Amersham Plc Inhibitor imaging agents
US7431914B2 (en) 2003-11-24 2008-10-07 Ge Healthcare As Contrast agent
WO2005062828A2 (en) 2003-12-23 2005-07-14 Bracco Imaging S.P.A. New compounds useful as metal chelators
CN1993357B (zh) 2004-07-02 2011-10-19 伯拉考成像股份公司 用于磁共振成像(mri)的含有具有多羟基化取代基的螯合部分的高弛豫造影剂
FR2891830B1 (fr) * 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013209400A (ja) * 2005-10-07 2013-10-10 Guerbet 医用画像のための短いアミノアルコール鎖および金属錯体を含む化合物

Also Published As

Publication number Publication date
DK1931673T3 (da) 2012-10-08
NL301259I2 (nl) 2024-03-25
KR101440761B1 (ko) 2014-09-17
KR20080080495A (ko) 2008-09-04
JP2013209400A (ja) 2013-10-10
KR20140060565A (ko) 2014-05-20
US20090169479A1 (en) 2009-07-02
CA2625207C (en) 2014-05-13
FR2891830B1 (fr) 2011-06-24
ES2519369T3 (es) 2014-11-06
FR24C1006I2 (fr) 2025-02-07
FR24C1006I1 (fr) 2024-04-19
PT1931673E (pt) 2012-09-24
JP2009513574A (ja) 2009-04-02
BRPI0617151B8 (pt) 2021-07-27
EP2457914A1 (en) 2012-05-30
PL1931673T3 (pl) 2012-11-30
CN103224495A (zh) 2013-07-31
WO2007042506A1 (en) 2007-04-19
CN103224495B (zh) 2015-07-15
FIC20240003I1 (fi) 2024-02-26
CN101305006B (zh) 2013-04-24
US8114863B2 (en) 2012-02-14
CA2625207A1 (en) 2007-04-19
BE2024C510I2 (enExample) 2026-01-14
ES2390092T3 (es) 2012-11-06
EP1931673A1 (en) 2008-06-18
CN101305006A (zh) 2008-11-12
BRPI0617151A2 (pt) 2011-07-12
EP2457914B1 (en) 2014-08-06
FR2891830A1 (fr) 2007-04-13
EP1931673B1 (en) 2012-08-29
JP5731572B2 (ja) 2015-06-10
BRPI0617151B1 (pt) 2020-08-11

Similar Documents

Publication Publication Date Title
JP5731572B2 (ja) 医用画像のための短いアミノアルコール鎖および金属錯体を含む化合物
JP5368099B2 (ja) ガリウムと錯体形成することが可能なシグナル部分にカップリングされた、生物学的標的の認識のための部分を含んでなる化合物
US11401262B2 (en) Dimeric contrast agents
US10793533B2 (en) Dimeric contrast agents
US9463254B2 (en) Molecular design toward dual-modality probes for radioisotope-based imaging (PET or SPECT) and MRI

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090925

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120815

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120921

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120928

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121019

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130520

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130611

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130703

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130705

R150 Certificate of patent or registration of utility model

Ref document number: 5317270

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250